VCN-01 moves toward Phase 2/3 retinoblastoma trial after Theriva completes study design
Theriva designs a Phase 2/3 VCN-01 retinoblastoma trial after early eye-preservation signals. See what the planned FDA meeting could change.
Pharma & Biotech